Bipolar I Disorder
Conditions
Keywords
Bipolar I disorder, Bipolar depression, NMDA
Brief summary
At present, the treatment of Bipolar I disorder (BD-I), especially its depressive episode (bipolar depression), is still limited, because there is no effective treatment for the associated cognitive impairment and perceived stress. NMDA receptor (NMDAR) dysfunction is associated with BD-I, particularly its cognitive impairment and perceived stress. This study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) in the treatment of cognitive impairment and perceived stress in the patients with bipolar depression.
Detailed description
Bipolar I disorder (BD-I) is a severe brain disorder. At present, the treatment of BD-I, especially its depressive episode (bipolar depression), is still limited, because there is no effective treatment for the associated cognitive impairment and perceived stress. This study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) in the treatment of cognitive impairment and perceived stress in the patients with bipolar depression. The subjects are bipolar depression patients. They have been treated for bipolar depression for at least four weeks but remain depressive. Participating in this study, they will continue the original treatment, and will be randomized, double-blindly to receive the NMDAE or placebo for 8 weeks. We will measure 6 cognitive domains (including 9 cognitive tests) and quality of life at weeks 0 and 8; and assess the Perceived Stress Scale, Global Assessment of Function (GAF), various scales for clinical symptoms, and side effects at weeks 0, 2, 4, 6, and 8. The efficacies of NMDAE and placebo will be compared. Chi-square (or Fisher's exact test) will be used to compare differences of categorical variables and t-test (or Mann-Whitney test if the distribution is not normal) for continuous variables between treatment groups. Mean changes from baseline in repeated-measure assessments will be assessed using the generalized estimating equation (GEE). All p values for clinical measures will be based on two-tailed tests with a significance level of 0.05.
Interventions
DRUGNMDAE
Use of an NMDA enhancer for the treatment of bipolar depression
DRUGPlacebo Cap
Use of placebo as a comparator.
Sponsors
National Science and Technology Council
China Medical University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Are 18 to 65 years of age; * Satisfy a DSM-5-TR (American Psychiatric Association) diagnosis of BD-I, current episode depressed, after treatment of stable (i.e., at least 4 weeks) and adequate treatment of antipsychotic (quetiapine or lurasidone) and/or mood stabilizer; * Have a 17-item Hamilton Depression Rating Scale (HAMD) score ≥18 and a Young Mania Rating Scale (YMRS) score ≤7 at baseline; * Agree to participate in the study and provide informed consent
Exclusion criteria
* Current substance abuse or history of substance dependence in the past 6 months * History of epilepsy, head trauma, stroke or other serious medical or neurological illness which may interfere with the study * Schizophrenia or other psychotic disorder * Moderate-severe suicidal risks * Severe cognitive impairment * Clinically significant laboratory screening tests (including blood routine, biochemical tests) * Pregnancy or lactation; * Inability to follow protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Perceived Stress Scale in Perceived Stress Scale | week 0, 2, 4, 6, 8 | Assessment of stress and anxiety symptoms Minimum value: 0, maximum value:56, the higher scores mean a worse outcome. |
| Change in Logical Memory Test of the Wechsler Memory Scale | week 0, 8 | Assessment of episodic memory |
| Digit Span | week 0, 8 | Assessment of verbal working memory |
| Spatial Span | week 0, 8 | Assessment of nonverbal working memory |
| Category Fluency | week 0, 8 | Assessment of speed of processing |
| Trail Marking A | week 0, 8 | Assessment of speed of processing |
| WAIS-III Digit Symbol-Coding | week 0, 8 | Assessment of speed of processing |
| Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) V2.0 | week 0, 8 | Assessment of social cognition |
| Change in Visual Continuous Performance Test | week 0, 8 | Assessment of sustained attention |
| Change in Wisconsin Card Sorting Test | week 0, 8 | Assessment of abstract and shift set |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Quality of life (SF-36) | week 0, 8 | — |
| Change in Global Assessmeint of Functioning | Week 0, 2, 4, 6, 8 | Assessment of global improvement. Minimum value: 1, maximum value:100, the higher scores mean a better outcome. |
| Change in Hamilton Rating Scale for Depression | Week 0, 2, 4, 6, 8 | Assessment of depressive symptoms. Minimum value: 0, maximum value:52, the higher scores mean a worse outcome. |
| Change in Montgomery-Åsberg Depression Rating Scale | Week 0, 2, 4, 6, 8 | Assessment of depressive symptoms. Minimum value: 0, maximum value:60, the higher scores mean a worse outcome. |
| Change in Young Mania Rating Scale | Week 0, 2, 4, 6, 8 | Assessment of manic symptoms. Minimum value: 0, maximum value:60, the higher scores mean a worse outcome. |
| Change in Beck Scale for Suicide Ideation | Week 0, 2, 4, 6, 8 | Assessment of Suicide Ideation. Minimum value: 0, maximum value:38, the higher scores mean a greater risk of suicide. |
| Change in Clinical Global Impression Scale | Week 0, 2, 4, 6, 8 | — |
Countries
Taiwan
Contacts
Primary ContactHsien-Yuan Lane Lane, M.D., Ph.D
Outcome results
None listed